Sep. 11 at 5:04 AM
$PGEN Something to keep in mind.
If
$INO gets approved in ~50 days on the Oct. 30 PDUFA, there’s a very real chance PGEN takes a 30%–40% hit, maybe more. That’s just reality when two companies are treating the same rare disease and one is valued around
$2.4B while the other is sitting around
$130M.
The market will have to start asking whether a ~
$130M INO valuation makes sense if INO-3107 gets FDA approval. Two RRP players can coexist, but that valuation gap is pretty damn hard to ignore.
Just saying. 👀
